Rare genetic mutations shed light on the pathogenesis of Parkinson disease

Journal of Clinical Investigation

Volumn 111, Issue 2, 2003, Pages 145-151

  Dawson, Ted M ^a   Dawson, Valina L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DJ 1 PROTEIN; PARKIN; PROTEASOME; PROTEIN; PROTEIN CDCREL 1; SYNPHILIN 1; SYNUCLEIN; UBIQUITIN; UNCLASSIFIED DRUG;

BIOCHEMISTRY; GENE MUTATION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; REVIEW; SUBSTANTIA NIGRA; SYNAPSE;

HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGASES; MUTATION; NERVE TISSUE PROTEINS; ONCOGENE PROTEINS; PARKINSON DISEASE; SYNUCLEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 0037240325     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200317575     Document Type: Review

References (68)

1. Lang, A.E., and Lozano, A.M. 1998. Parkinson's disease. Second of two parts. N. Engl. J. Med. 339:1130-1143.
2. Lang, A.E., and Lozano, A.M. 1998. Parkinson's disease. First of two parts. N. Engl. J. Med. 339:1044-1053.
3. Forno, L.S. 1996. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55:259-272.
4. Gasser, T. 2001. Genetics of Parkinson's disease. J. Neurol. 248:833-840.
5. Roses, A.D. 1998. Apolipoprotein E and Alzheimer's disease. The tip of the susceptibility iceberg. Ann. NY Acad. Sci. 855:738-743.
6. Dawson, T., Mandir, A., and Lee, M. 2002. Animal models of PD: pieces of the same puzzle? Neuron. 35:219-222.
7. Giasson, B.I., and Lee, V.M. 2001. Parkin and the molecular pathways of Parkinson's disease. Neuron. 31:885-888.
8. Polymeropoulos, M.H., et al. 1996. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science. 274:1197-1199.
9. Polymeropoulos, M.H., et al. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276:2045-2047.
10. Kitada, T., et al. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 392:605-608.
11. Bonifati, V., et al. 2002. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. doi:10.1126/ science.1077209.
12. Liu, Y., Fallon, L., Lashuel, H.A., Liu, Z., and Lansbury, P.T., Jr. 2002. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell. 111:209-218.
13. Gasser, T., et at. 1998. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat. Genet. 18:262-265.
14. Farrer, M., et al. 1999. A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum. Mol. Genet. 8:81-85.
15. Muenter, M.D., et al. 1998. Hereditary form of parkinsonism - dementia. Ann. Neurol. 43:768-781.
16. Valence, E.M., et al. 2001. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am. J. Hum. Genet. 68:895-900.
17. van Duijn, C.M., et al. 2001. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am. J. Hum. Genet. 69:629-634.
18. Funayama, M., et al. 2002. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13. 1. Ann. Neurol. 51:296-301.
19. Hampshire, D.J., et al. 2001. Ku£or-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36. J. Med. Genet. 38:680-682.
20. Sveinbjornsdottir, S., et al. 200C. Familial aggregation of Parkinson's disease in Iceland. N. Engl. J. Med. 343:1765-1770.
21. Hicks, A.A., et al. 2002. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann. Neurol. 52:549-555.
22. Scott, W.K., et al. 2001. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA. 286:2239-2244.
23. Martin, E.R., et al. 2001. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA. 286:2245-2250.
24. Maraganore, D.M., et al. 2001. Case-control study of the extended tau gene haplotype in Parkinson's disease. Ann. Neurol. 50:658-661.
25. Golbe, L.I., et al. 2001. The tau A0 allele in Parkinson's disease. Mov. Disord. 16:442-447.
26. Pastor, P., et al. 2001. Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene. Ann. Neurol. 49:263-267.
27. Hutton, M., et al. 1998. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 393:702-705.
28. DeStefano, A.L., et al. 2001. Genome-wide scan for Parkinson's disease: the GenePD Study. Neurology. 57:1124-1126.
29. Li, Y.J., et al. 2002. Age at onset in two common neurodegenerative diseases is genetically controlled. Am. J. Hum. Genet. 70:985-993.
30. Tanner, C.M., et al. 1999. Parkinson disease in twins: an etiologic study. JAMA. 281:341-346.
31. Papadimitriou, A., et al. 1999. Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance? Neurology. 52:651-654.
32. Kruger, R., et al. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18:106-108.
33. Farrer, M., et al. 2001. alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Genet. 10:1847-1851.
34. Clayton, D.F., and George, J.M. 1998. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21:249-254.
35. Murray, I.V.J., Lee, V.M., and Trojanowski, J.Q. 2001. Synucleinopathies: a pathological and molecular review. Clinical Neuroscience Research. 1:445-455.
36. Abeliovich, A., et al. 2000. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 25:239-252.
37. Masliah, E., er al. 2000. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 287:1265-1269.
38. Giasson, B.I., et al. 2002. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron. 34:521-533.
39. Lee, M.K., and Price, D.L. 2001. Advances in genetic models of Parkinson's Disease. Clinical Neuroscience Research. 1:456-466.
40. Lee, M.K., et al. 2002. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 right-arrow Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA. 99:8968-8973.
41. Kahle, P.J., et al. 2000. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 20:6365-6373.
42. Matsuoka, Y., et al. 2001. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8:535-539.
43. Richfield, E,K., et al. 2002. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 175:35-48.
44. van der Putten, H., et al. 2000. Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20:6021-6029.
45. Hashimoto, M., Rockenstein, E., Mante, M., Mallory, M., and Masliah, E. 2001. β-Synuclein inhibits α-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron. 32:213-223.
46. Feany, M.B., and Bender, W.W. 2000. A Drosophila model of Parkinson's disease. Nature. 404:394-398.
47. Auluck, P.K., Chan, H.Y.E., Trojanowski, J.Q., Lee, V.M., and Bonini, N.M. 2001. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science. 295:865-868.
48. Tanaka, Y., et al. 2001. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10:919-926.
49. Conway, K.A., Rochet, J.C., Bieganski, R.M., and Lansbury, P.T., Jr. 2001. Kinetic stabilization of the alpha-synuclein prorofibril by a dopamine-alpha-synuclein adduct. Science. 294:1346-1349.
50. Xu, J., et al. 2002. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8:600-606.
51. Matsumine, H., et al. 1997. Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am. J. Hum. Genet. 60:588-596.
52. Zhang, Y., Dawson, V.L., and Dawson, T.M. 2001. Parkin: clinical aspects and neurobiology. Clinical Neuroscience Research. 1:467-482.
53. Lucking, C.B., et al. 2000. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N. Engl. J. Med. 342:1560-1567.
54. Dawson, T.M. 2000. New animal models for Parkinson's disease. Cell. 101:115-118.
55. Zhang, Y., et al. 2000. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. USA. 97:13354-13359.
56. Chung, K.K., Dawson, V.L., and Dawson, T.M. 2001. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci. 24(Suppl.):S7-S14.
57. Shimura, H., et al. 2000. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25:302-305.
58. Imai, Y., Soda, M., and Takahashi, R. 2000. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275:35661-35664.
59. Beites, C.L., Xie, H., Bowser, R., and Trimble, W.S. 1999. The septin CDCrel-1 binds syntaxin and inhibits exocytosis. Nat. Neurosci. 2:434-439.
60. Chung, K.K., et al. 2001. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med. 7:1144-1150.
61. Engelender, S., et al. 1999. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet. 22:110-114.
62. Wakabayashi, K., et al. 2000. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann. Neurol. 47:521-523.
63. Farrer, M., et al. 2001. Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 50:293-300.
64. Shimura, H., et al. 2001. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science. 293:263-269.
65. Imai, Y., et al. 2001. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell. 105:891-902.
66. Mitsumoto, A., and Nakagawa, Y. 2001. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic. Res. 35:885-893.
67. Takahashi, K., et al. 2001. DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor. J. Biol. Chem. 276:37556-37563.
68. McNaught, K.S., Olanow, C.W., Halliwell, B., Isacson, O., and Jenner, P. 2001. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2:589-594.